Login / Signup

Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.

Qingsheng XuKaiyuan HuangXiangqi MengYuxiang WengLuyuan ZhangLinghao BuXiujue ZhengJinquan CaiRen-Ya ZhanQun Chen
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Anlotinib combined with temozolomide is efficacious and tolerated in recurrent GBM patients.
Keyphrases
  • newly diagnosed
  • end stage renal disease
  • ejection fraction
  • prognostic factors
  • peritoneal dialysis
  • patient reported outcomes